Anti-tumor efficacy of paclitaxel against human lung cancer xenografts

Japanese Journal of Cancer Research

Volumn 88, Issue 12, 1997, Pages 1205-1210

  Yamori, Takao ^a   Sato, Shigeo ^a   Chikazawa, Hirotaka ^b   Kadota, Toshihito ^b  

^a CANCER CHEMOTHERAPY CENTER   (Japan)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

Anti tumor efficacy; Human lung cancer; In vitro; In vivo; Paclitaxel

Indexed keywords

CISPLATIN; CREMOPHOR; PACLITAXEL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TUMOR XENOGRAFT; WEIGHT REDUCTION;

EID: 0031470891     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.1997.tb00350.x     Document Type: Article

References (22)

1. Wani, M. C., Taylor, H. L., Wall, M. E., Coggon, P. and McPhail, A. T. Plant anti tumor agents. IV. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J. Am. Chem. Soc., 93, 2325-2327 (1971).
2. Schiff, P. B., Fant, J. and Horwitz, S. B. Promotion of microtubule assembly in vitro by taxol. Nature, 277, 665-667 (1979).
3. Schiff, P. B. and Horwitz, S. B. Taxol stabilizes microtubules in mouse fibroblast cells. Proc. Natl. Acad. Sci. USA, 77, 1561-1565 (1980).
4. Holmes, E. C., Livingston, R. and Turrisi, A., III. Neoplasms of the thorax. In "Cancer Medicine," ed. J. F. Holland, E. Frei, III, R. C. Bast, Jr., D. W. Kufe, D. L. Morton and R. R. Weichselbaum, pp. 1285-1337 (1993). Lea and Febiger, Philadelphia, London.
5. Murphy, W. K., Fossella, F. V., Winn, R. J., Shin, D. M., Hynes, H. E., Gross, H. M., Davilla, E., Leimert, J., Dhingra, H., Raber, M. N., Krakoff, I. H. and Hong, W. K. Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. J. Natl. Cancer Inst., 85, 384-388 (1993).
6. Sekine, I., Nishiwaki, Y., Watanabe, K., Yoneda, S., Saijo, N. and the East Japan Paclitaxel Study Group. Phase II study of 3-hour infusion of paclitaxel in previously untreated non-small cell lung cancer. Clin. Cancer Res., 2, 941-945 (1996).
7. Edelman, M. J. and Gandara, D. R. Promising new agents in the treatment of non-small cell lung cancer. Cancer Chemother. Pharmacol., 37, 385-393 (1996).
8. Rose, W. C. Taxol: a review of its preclinical in vivo antitumor activity. Anti-Cancer Drugs, 3, 311-321 (1992).
9. Keiner, M. J., Mcmorris, T. C., Estes, L., Starr, R., Samson, K., Varki, N. and Taetle, R. Nonresponsiveness of the metastatic human lung carcinoma MV522 xenograft to conventional anticancer agents. Anticancer Res., 15, 867-872 (1995).
10. Monks, A., Scudiero, D., Skehan, P., Shoemaker, R., Paull, K., Vistica, D., Hose, C., Langley, J., Cronise, P., Vaigro-Wolff, A., Gray-Goodrich, M., Campbell, H., Mayo, J., Boyd, M. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J. Natl. Cancer Inst., 83, 757-766 (1991).
11. Yamori, T. A human cell line panel for screening anticancer drugs. Jpn. J. Cancer Chemother., 24, 129-135 (1997) (in Japanese).
12. Stinson, S. F., Alley, M. C., Kopp, W. C., Fiebig, H.-H., Mullendore, L. A., Pittman, A. F., Kenney, S., Keller, J., Boyd, M. R. Morphological and immunocytochemical characteristics of human tumor cell lines for use in a disease-oriented anticancer drug screen. Anticancer Res., 12, 1035-1053 (1992).
13. Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D., Warren, J. T., Bokesch, H., Kenney, S. and Boyd, M. R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst., 82, 1107-1112 (1990).
14. Fujimoto, S. Schedule dependency of IV-paclitaxel against SC-M109 mouse lung cancer. Jpn. J. Cancer Chemother., 21, 671-677 (1994). (in Japanese)
15. Perego, P., Giarola, M., Righetti, S. C., Supino, R., Caserini, C., Delia, D., Pierotti, M. A., Miyashita, T., Reed, J. C. and Zunino, F. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell system. Cancer Res., 56, 556-562 (1996).
16. Wahl, A. F., Donaldson, K. L., Fairchild, C., Lee, F. Y., Foster, S. A., Demers, G. W. and Galloway, D. A. Loss of normal p53 function confers sensitization of taxol by increasing G2/M arrest and apoptosis. Nat. Med., 2, 72-79 (1996).
17. Weinstein, J. N., Myers, T. G., O'Connor, P. M., Friend, S. H., Fornace Jr., A. J., Kohn, K. W., Fojo, T., Bates, S. E., Rubinstein, L. V., Anderson, N. L., Buolamwini, J. K., van Osdol, W. W., Monks, A. P., Scudiero, D. A., Sausville, E. A., Zaharevitz, D. W., Bunow, B., Viswanadhan, V. N., Johnson, G. S., Wittes, R. E. and Paull, K. D. An information-intensive approach to the molecular pharmacology of cancer. Science, 275, 343-349 (1997).
18. Engblom, P., Rantanen, V., Kulmala, J. and Grenman, S. Paclitaxel and cisplatin sensitivity of ovarian carcinoma cell lines tested with the 96-well plate clonogenic assay. Anticancer Res., 16, 1743-1748 (1996).
19. Ohtsu, T., Sasaki, Y., Tamura, T., Miyata, Y., Nakanomyo, H., Nishiwaki, Y. and Saijo, N. Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion. Clin. Cancer Res., 1, 599-606 (1995).
20. Kubota, T., Matsuzaki, S. W., Hoshiya, Y., Watanabe, M., Kitajima, M., Asanuma, F., Yamada, Y. and Koh, J. Antitumor activity of paclitaxel against human breast carcinoma xenografts serially transplanted into nude mice. J. Surg. Oncol., 64, 115-121 (1997).
21. Riondel, J., Jacrot, M., Picot, F., Beriel, H., Mouriquand, C. and Potier, P. Therapeutic response to taxol of six human tumors xenografted into nude mice. Cancer Chemother. Pharmacol., 17, 137-142 (1986).
22. Sternberg, C. N., Sordillo, P. P., Cheng, E., Chuang, Y. J. and Niedzwiecki, D. Evaluation of new anticancer agents against human pancreatic carcinomas in nude mice. Am. J. Clin. Oncol., 10, 219-221 (1987).